Pharmacokinetics and Safety of Icotinib Hydrochloride Cream in Patients with Mild to Moderate Chronic Plaque Psoriasis: A Randomized Double-Blind Vehicle-Controlled Phase 1 Study.
Conclusion: This phase 1 study demonstrated favorable safety, tolerable toxicity, and preliminary efficacy of icotinib cream in patients with mild to moderate psoriasis. The dose concentration of 2.0% (twice daily based on the fingertip unit method) is recommended for further study.
Study Design: This is a single-center, randomized, double-blind, and vehicle-controlled study.
PMID: 31187048 [PubMed - in process]
Source: Biomed Res - Category: Research Authors: Liu L, Lou H, Zhou J, Shen Y, Zheng M, Ruan Z Tags: Biomed Res Int Source Type: research
More News: China Health | Dermatology | Drugs & Pharmacology | Laboratory Medicine | Psoriasis | Research | Skin | Study | Toxicology